epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Arbli

losartan

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Fetal Toxicity

fetal/neonatal morbidity/mortality may occur when drugs that act directly on the renin-angiotensin system are used in pregnancy; D/C drug ASAP once pregnancy detected

Adult Dosing .

Dosage forms:  SUSPENSION: 10 mg per mL

HTN

[50-100 mg/day PO divided qd-bid]
Start: 50 mg PO qd; Max: 100 mg/day; Info: start 25 mg PO qd if on diuretic

nephropathy, diabetic

[50-100 mg PO qd]
Start: 50 mg PO qd; Max: 100 mg/day; Info: for patients with type 2 DM and HTN

stroke prevention

[50-100 mg PO qd]
Start: 50 mg PO qd; Max: 100 mg/day; Info: for patients with HTN and LVH; possibly ineffective in Black patients; may give with HCTZ

heart failure with reduced ejection fraction (off-label)

[50-150 mg PO qd]
Start: 25-50 mg PO qd; Max: 150 mg/day

renal dosing

[see below]
renal impairment: no adjustment
HD/PD: not defined

hepatic dosing

[adjust dose amount]
mild-moderate impairment: start 25 mg qd; severe impairment: not defined

Peds Dosing .

Dosage forms:  SUSPENSION: 10 mg per mL

HTN

[6 yo and older]
Dose: 0.7-1.4 mg/kg/dose PO qd; Start: 0.7 mg/kg/dose PO qd up to 50 mg/day; Max: 1.4 mg/kg/day up to 100 mg/day

aortic dilation, Marfan syndrome-associated (off-label)

[1 yo and older]
Dose: 1-1.4 mg/kg/dose PO qd; Start: 0.4 mg/kg/dose PO qd; Max: 100 mg/day

renal dosing

[see below]
CrCl >30: no adjustment; CrCl <30: not defined
HD/PD: not defined

hepatic dosing

[not defined]
hepatic impairment: consider adult hepatic dosing for guidance

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@5b217412
  • hypersensitivity to drug or ingredient
  • pregnancy
  • caution: Black patients (possibly ineffective in stroke prevention use)
  • caution: Black patients (incr. risk of angioedema)
  • caution: renal disease
  • caution: renal artery stenosis
  • caution: renal impairment
  • caution: hepatic impairment
  • caution: volume depletion
  • caution: hyponatremia
  • caution: hyperkalemia risk
  • caution: CHF, severe

Drug Interactions .

Overview

losartan

ARB

Interaction Characteristics:
  • angiotensin II Type 1 antagonist
  • antihypertensive agent
  • decreases renal perfusion/fxn
  • hyperkalemia
  • hypoglycemic effects

Contraindicated

  • aliskiren
  • Arbli (losartan)
    +
    aliskiren
    1 interaction

    Contraindicated

    losartan + aliskiren

    contraindicated in diabetic patients; avoid combo in pts w/ CrCl <60; for all other pts, use alternative or monitor BP, potassium, renal fxn: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • isocarboxazid
  • Arbli (losartan)
    +
    isocarboxazid
    1 interaction

    Contraindicated

    losartan + isocarboxazid

    contraindicated: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • sparsentan
  • Arbli (losartan)
    +
    sparsentan
    1 interaction

    Contraindicated

    losartan + sparsentan

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

Avoid/Use Alternative

  • aldesleukin
  • Arbli (losartan)
    +
    aldesleukin
    1 interaction

    Avoid/Use Alternative

    losartan + aldesleukin

    avoid combo: combo may incr. risk of severe or life-threatening hypotension (additive effects)

  • amikacin
  • Arbli (losartan)
    +
    amikacin
    1 interaction

    Avoid/Use Alternative

    losartan + amikacin

    use alternative or monitor amikacin levels, renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • amiloride
  • Arbli (losartan)
    +
    amiloride
    1 interaction

    Avoid/Use Alternative

    losartan + amiloride

    if hypokalemia use, monitor potassium; otherwise, avoid combo: combo may incr. risk of hyperkalemia (additive effects)

  • angiotensin II
  • Arbli (losartan)
    +
    angiotensin II
    1 interaction

    Avoid/Use Alternative

    losartan + angiotensin II

    use alternative or monitor BP: combo may decr. angiotensin II efficacy (antagonistic effects)

  • aripiprazole lauroxil
  • Arbli (losartan)
    +
    aripiprazole lauroxil
    1 interaction

    Avoid/Use Alternative

    losartan + aripiprazole lauroxil

    ARISTADA INITIO: avoid combo; ARISTADA: monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • azilsartan medoxomil
  • Arbli (losartan)
    +
    azilsartan medoxomil
    1 interaction

    Avoid/Use Alternative

    losartan + azilsartan medoxomil

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

  • benazepril
  • Arbli (losartan)
    +
    benazepril
    1 interaction

    Avoid/Use Alternative

    losartan + benazepril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • candesartan cilexetil
  • Arbli (losartan)
    +
    candesartan cilexetil
    1 interaction

    Avoid/Use Alternative

    losartan + candesartan cilexetil

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

  • captopril
  • Arbli (losartan)
    +
    captopril
    1 interaction

    Avoid/Use Alternative

    losartan + captopril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • clofarabine
  • Arbli (losartan)
    +
    clofarabine
    1 interaction

    Avoid/Use Alternative

    losartan + clofarabine

    avoid losartan during 5 day clofarabine tx; monitor CBC, renal fxn, BP: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, severe hypotension, other adverse effects (additive effects)

  • enalapril
  • Arbli (losartan)
    +
    enalapril
    1 interaction

    Avoid/Use Alternative

    losartan + enalapril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • enalaprilat
  • Arbli (losartan)
    +
    enalaprilat
    1 interaction

    Avoid/Use Alternative

    losartan + enalaprilat

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • fosinopril
  • Arbli (losartan)
    +
    fosinopril
    1 interaction

    Avoid/Use Alternative

    losartan + fosinopril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • irbesartan
  • Arbli (losartan)
    +
    irbesartan
    1 interaction

    Avoid/Use Alternative

    losartan + irbesartan

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

  • lisinopril
  • Arbli (losartan)
    +
    lisinopril
    1 interaction

    Avoid/Use Alternative

    losartan + lisinopril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • lofexidine
  • Arbli (losartan)
    +
    lofexidine
    1 interaction

    Avoid/Use Alternative

    losartan + lofexidine

    use alternative or monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • losartan
  • Arbli (losartan)
    +
    losartan
    1 interaction

    Avoid/Use Alternative

    losartan + losartan

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

  • moexipril
  • Arbli (losartan)
    +
    moexipril
    1 interaction

    Avoid/Use Alternative

    losartan + moexipril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • olmesartan medoxomil
  • Arbli (losartan)
    +
    olmesartan medoxomil
    1 interaction

    Avoid/Use Alternative

    losartan + olmesartan medoxomil

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

  • perindopril
  • Arbli (losartan)
    +
    perindopril
    1 interaction

    Avoid/Use Alternative

    losartan + perindopril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • potassium chloride
  • Arbli (losartan)
    +
    potassium chloride
    1 interaction

    Avoid/Use Alternative

    losartan + potassium chloride

    IV potassium chloride: use alternative or monitor potassium, ECG; ORAL potassium: monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • potassium phosphate
  • Arbli (losartan)
    +
    potassium phosphate
    1 interaction

    Avoid/Use Alternative

    losartan + potassium phosphate

    use alternative or monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • quinapril
  • Arbli (losartan)
    +
    quinapril
    1 interaction

    Avoid/Use Alternative

    losartan + quinapril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • ramipril
  • Arbli (losartan)
    +
    ramipril
    1 interaction

    Avoid/Use Alternative

    losartan + ramipril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • tacrolimus
  • Arbli (losartan)
    +
    tacrolimus
    1 interaction

    Avoid/Use Alternative

    losartan + tacrolimus

    consider alternative or monitor tacrolimus levels, renal fxn, potassium, BP: combo may incr. tacrolimus levels, risk of nephrotoxicity, hyperkalemia, other adverse effects; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • telmisartan
  • Arbli (losartan)
    +
    telmisartan
    1 interaction

    Avoid/Use Alternative

    losartan + telmisartan

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

  • trandolapril
  • Arbli (losartan)
    +
    trandolapril
    1 interaction

    Avoid/Use Alternative

    losartan + trandolapril

    use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • trimethoprim
  • Arbli (losartan)
    +
    trimethoprim
    1 interaction

    Avoid/Use Alternative

    losartan + trimethoprim

    avoid combo: combo may incr. risk of hyperkalemia (additive effects)

  • valsartan
  • Arbli (losartan)
    +
    valsartan
    1 interaction

    Avoid/Use Alternative

    losartan + valsartan

    avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

  • abiraterone acetate
  • Arbli (losartan)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    losartan + abiraterone acetate

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • acyclovir
  • Arbli (losartan)
    +
    acyclovir
    1 interaction

    Monitor/Modify Tx

    losartan + acyclovir

    monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • adefovir dipivoxil
  • Arbli (losartan)
    +
    adefovir dipivoxil
    1 interaction

    Monitor/Modify Tx

    losartan + adefovir dipivoxil

    monitor renal fxn: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased, additive effects)

  • albuterol
  • Arbli (losartan)
    +
    albuterol
    1 interaction

    Monitor/Modify Tx

    losartan + albuterol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • albuterol inhaled
  • Arbli (losartan)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + albuterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • alfentanil
  • Arbli (losartan)
    +
    alfentanil
    1 interaction

    Monitor/Modify Tx

    losartan + alfentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • alfuzosin
  • Arbli (losartan)
    +
    alfuzosin
    1 interaction

    Monitor/Modify Tx

    losartan + alfuzosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • allopurinol
  • Arbli (losartan)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    losartan + allopurinol

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • almotriptan
  • Arbli (losartan)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    losartan + almotriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • alprostadil intracavernous
  • Arbli (losartan)
    +
    alprostadil intracavernous
    1 interaction

    Monitor/Modify Tx

    losartan + alprostadil intracavernous

    monitor BP: combo may increase risk of hypotension (additive effects)

  • amantadine
  • Arbli (losartan)
    +
    amantadine
    1 interaction

    Monitor/Modify Tx

    losartan + amantadine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amifostine
  • Arbli (losartan)
    +
    amifostine
    1 interaction

    Monitor/Modify Tx

    losartan + amifostine

    D/C losartan 24h before amifostine admin.; monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

  • amikacin inhaled
  • Arbli (losartan)
    +
    amikacin inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + amikacin inhaled

    monitor renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • amitriptyline
  • Arbli (losartan)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    losartan + amitriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • amoxapine
  • Arbli (losartan)
    +
    amoxapine
    1 interaction

    Monitor/Modify Tx

    losartan + amoxapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • amphetamine
  • Arbli (losartan)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    losartan + amphetamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amphotericin
  • Arbli (losartan)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    losartan + amphotericin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • anthrax immune globulin
  • Arbli (losartan)
    +
    anthrax immune globulin
    1 interaction

    Monitor/Modify Tx

    losartan + anthrax immune globulin

    monitor renal fxn; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • apomorphine
  • Arbli (losartan)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    losartan + apomorphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • apraclonidine ophthalmic
  • Arbli (losartan)
    +
    apraclonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + apraclonidine ophthalmic

    monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of hypotension (additive effects)

  • arformoterol inhaled
  • Arbli (losartan)
    +
    arformoterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + arformoterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • aripiprazole bimonthly injection
  • Arbli (losartan)
    +
    aripiprazole bimonthly injection
    1 interaction

    Monitor/Modify Tx

    losartan + aripiprazole bimonthly injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aripiprazole monthly injection
  • Arbli (losartan)
    +
    aripiprazole monthly injection
    1 interaction

    Monitor/Modify Tx

    losartan + aripiprazole monthly injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • aripiprazole oral
  • Arbli (losartan)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    losartan + aripiprazole oral

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • armodafinil
  • Arbli (losartan)
    +
    armodafinil
    1 interaction

    Monitor/Modify Tx

    losartan + armodafinil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • articaine
  • Arbli (losartan)
    +
    articaine
    1 interaction

    Monitor/Modify Tx

    losartan + articaine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • asciminib
  • Arbli (losartan)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    losartan + asciminib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • asenapine
  • Arbli (losartan)
    +
    asenapine
    1 interaction

    Monitor/Modify Tx

    losartan + asenapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aspirin
  • Arbli (losartan)
    +
    aspirin
    1 interaction

    Monitor/Modify Tx

    losartan + aspirin

    monitor BP, renal fxn: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • atogepant
  • Arbli (losartan)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    losartan + atogepant

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • atomoxetine
  • Arbli (losartan)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    losartan + atomoxetine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • atropine ophthalmic
  • Arbli (losartan)
    +
    atropine ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + atropine ophthalmic

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • auranofin
  • Arbli (losartan)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    losartan + auranofin

    monitor renal fxn: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • avanafil
  • Arbli (losartan)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    losartan + avanafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • axitinib
  • Arbli (losartan)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    losartan + axitinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • balsalazide
  • Arbli (losartan)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    losartan + balsalazide

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • benzphetamine
  • Arbli (losartan)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    losartan + benzphetamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • berberine
  • Arbli (losartan)
    +
    berberine
    1 interaction

    Monitor/Modify Tx

    losartan + berberine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • betamethasone
  • Arbli (losartan)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    losartan + betamethasone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • betaxolol ophthalmic
  • Arbli (losartan)
    +
    betaxolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + betaxolol ophthalmic

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • bethanechol
  • Arbli (losartan)
    +
    bethanechol
    1 interaction

    Monitor/Modify Tx

    losartan + bethanechol

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • bevacizumab
  • Arbli (losartan)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    losartan + bevacizumab

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bexagliflozin
  • Arbli (losartan)
    +
    bexagliflozin
    1 interaction

    Monitor/Modify Tx

    losartan + bexagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • bismuth subsalicylate
  • Arbli (losartan)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    losartan + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bortezomib
  • Arbli (losartan)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    losartan + bortezomib

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • botulism immune globulin
  • Arbli (losartan)
    +
    botulism immune globulin
    1 interaction

    Monitor/Modify Tx

    losartan + botulism immune globulin

    monitor renal fxn; use lowest botulism immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • brexpiprazole
  • Arbli (losartan)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    losartan + brexpiprazole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • brigatinib
  • Arbli (losartan)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    losartan + brigatinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • brimonidine ophthalmic
  • Arbli (losartan)
    +
    brimonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + brimonidine ophthalmic

    monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of hypotension (additive effects)

  • brimonidine topical
  • Arbli (losartan)
    +
    brimonidine topical
    1 interaction

    Monitor/Modify Tx

    losartan + brimonidine topical

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • bromocriptine
  • Arbli (losartan)
    +
    bromocriptine
    1 interaction

    Monitor/Modify Tx

    losartan + bromocriptine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • budesonide
  • Arbli (losartan)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    losartan + budesonide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bumetanide
  • Arbli (losartan)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    losartan + bumetanide

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • bupivacaine
  • Arbli (losartan)
    +
    bupivacaine
    1 interaction

    Monitor/Modify Tx

    losartan + bupivacaine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • bupivacaine liposomal
  • Arbli (losartan)
    +
    bupivacaine liposomal
    1 interaction

    Monitor/Modify Tx

    losartan + bupivacaine liposomal

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • buprenorphine
  • Arbli (losartan)
    +
    buprenorphine
    1 interaction

    Monitor/Modify Tx

    losartan + buprenorphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • bupropion
  • Arbli (losartan)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    losartan + bupropion

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • butorphanol
  • Arbli (losartan)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    losartan + butorphanol

    monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)

  • cabergoline
  • Arbli (losartan)
    +
    cabergoline
    1 interaction

    Monitor/Modify Tx

    losartan + cabergoline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cabozantinib
  • Arbli (losartan)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    losartan + cabozantinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • caffeine
  • Arbli (losartan)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    losartan + caffeine

    monitor BP; avoid excessive caffeine intake: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • caffeine citrate
  • Arbli (losartan)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    losartan + caffeine citrate

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • canagliflozin
  • Arbli (losartan)
    +
    canagliflozin
    1 interaction

    Monitor/Modify Tx

    losartan + canagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cannabis
  • Arbli (losartan)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    losartan + cannabis

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • capecitabine
  • Arbli (losartan)
    +
    capecitabine
    1 interaction

    Monitor/Modify Tx

    losartan + capecitabine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • carboplatin
  • Arbli (losartan)
    +
    carboplatin
    1 interaction

    Monitor/Modify Tx

    losartan + carboplatin

    monitor CBC, renal fxn, ototoxicity: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • carfilzomib
  • Arbli (losartan)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    losartan + carfilzomib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cariprazine
  • Arbli (losartan)
    +
    cariprazine
    1 interaction

    Monitor/Modify Tx

    losartan + cariprazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • carteolol ophthalmic
  • Arbli (losartan)
    +
    carteolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + carteolol ophthalmic

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • celecoxib
  • Arbli (losartan)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    losartan + celecoxib

    monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • chloroprocaine
  • Arbli (losartan)
    +
    chloroprocaine
    1 interaction

    Monitor/Modify Tx

    losartan + chloroprocaine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • chlorothiazide
  • Arbli (losartan)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    losartan + chlorothiazide

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • chlorpromazine
  • Arbli (losartan)
    +
    chlorpromazine
    1 interaction

    Monitor/Modify Tx

    losartan + chlorpromazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • chlorthalidone
  • Arbli (losartan)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    losartan + chlorthalidone

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • cidofovir
  • Arbli (losartan)
    +
    cidofovir
    1 interaction

    Monitor/Modify Tx

    losartan + cidofovir

    monitor CBC, renal fxn: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • cilostazol
  • Arbli (losartan)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    losartan + cilostazol

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • cisplatin
  • Arbli (losartan)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    losartan + cisplatin

    monitor CBC, renal fxn, ototoxicity: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • clindamycin
  • Arbli (losartan)
    +
    clindamycin
    1 interaction

    Monitor/Modify Tx

    losartan + clindamycin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • clomipramine
  • Arbli (losartan)
    +
    clomipramine
    1 interaction

    Monitor/Modify Tx

    losartan + clomipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • clonidine
  • Arbli (losartan)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    losartan + clonidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • clozapine
  • Arbli (losartan)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    losartan + clozapine

    monitor BP, HR: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cocaine
  • Arbli (losartan)
    +
    cocaine
    1 interaction

    Monitor/Modify Tx

    losartan + cocaine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • codeine
  • Arbli (losartan)
    +
    codeine
    1 interaction

    Monitor/Modify Tx

    losartan + codeine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • coenzyme Q-10
  • Arbli (losartan)
    +
    coenzyme Q-10
    1 interaction

    Monitor/Modify Tx

    losartan + coenzyme Q-10

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • colistimethate
  • Arbli (losartan)
    +
    colistimethate
    1 interaction

    Monitor/Modify Tx

    losartan + colistimethate

    monitor renal fxn: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • copanlisib
  • Arbli (losartan)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    losartan + copanlisib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects, copanlisib may cause infusion-related HTN)

  • copper histidinate
  • Arbli (losartan)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    losartan + copper histidinate

    monitor renal fxn, electrolytes: combo may incr. risk of nephrotoxicity (additive effects)

  • corticotropin
  • Arbli (losartan)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    losartan + corticotropin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cortisone
  • Arbli (losartan)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    losartan + cortisone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • creatine
  • Arbli (losartan)
    +
    creatine
    1 interaction

    Monitor/Modify Tx

    losartan + creatine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • cyclophosphamide
  • Arbli (losartan)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    losartan + cyclophosphamide

    monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

  • cyclosporine
  • Arbli (losartan)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    losartan + cyclosporine

    monitor renal fxn, potassium, BP: combo may incr. risk of nephrotoxicity, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • cytomegalovirus immune globulin
  • Arbli (losartan)
    +
    cytomegalovirus immune globulin
    1 interaction

    Monitor/Modify Tx

    losartan + cytomegalovirus immune globulin

    monitor renal fxn; use lowest cytomegalovirus immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • danazol
  • Arbli (losartan)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    losartan + danazol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dapagliflozin
  • Arbli (losartan)
    +
    dapagliflozin
    1 interaction

    Monitor/Modify Tx

    losartan + dapagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • darbepoetin alfa
  • Arbli (losartan)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    losartan + darbepoetin alfa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • decitabine
  • Arbli (losartan)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    losartan + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hyperkalemia (additive effects)

  • deferasirox
  • Arbli (losartan)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    losartan + deferasirox

    monitor CBC, renal fxn, ototoxicity: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • deferoxamine
  • Arbli (losartan)
    +
    deferoxamine
    1 interaction

    Monitor/Modify Tx

    losartan + deferoxamine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • deflazacort
  • Arbli (losartan)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    losartan + deflazacort

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • denileukin diftitox
  • Arbli (losartan)
    +
    denileukin diftitox
    1 interaction

    Monitor/Modify Tx

    losartan + denileukin diftitox

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • desflurane
  • Arbli (losartan)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    losartan + desflurane

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • desipramine
  • Arbli (losartan)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    losartan + desipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • desmopressin
  • Arbli (losartan)
    +
    desmopressin
    1 interaction

    Monitor/Modify Tx

    losartan + desmopressin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • desvenlafaxine
  • Arbli (losartan)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    losartan + desvenlafaxine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dexamethasone
  • Arbli (losartan)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    losartan + dexamethasone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dexmedetomidine
  • Arbli (losartan)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    losartan + dexmedetomidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dexmedetomidine injection
  • Arbli (losartan)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    losartan + dexmedetomidine injection

    monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)

  • dexmethylphenidate
  • Arbli (losartan)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    losartan + dexmethylphenidate

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dextroamphetamine
  • Arbli (losartan)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    losartan + dextroamphetamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • diazoxide
  • Arbli (losartan)
    +
    diazoxide
    1 interaction

    Monitor/Modify Tx

    losartan + diazoxide

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • diclofenac
  • Arbli (losartan)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    losartan + diclofenac

    monitor BP, renal fxn, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of renal impairment, hyperkalemia (antagonistic effects; additive effects)

  • diclofenac topical
  • Arbli (losartan)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    losartan + diclofenac topical

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • diethylpropion
  • Arbli (losartan)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    losartan + diethylpropion

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • diflunisal
  • Arbli (losartan)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    losartan + diflunisal

    monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • dihydrocodeine
  • Arbli (losartan)
    +
    dihydrocodeine
    1 interaction

    Monitor/Modify Tx

    losartan + dihydrocodeine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • dihydroergotamine
  • Arbli (losartan)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    losartan + dihydroergotamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dinutuximab
  • Arbli (losartan)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    losartan + dinutuximab

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • dipyridamole
  • Arbli (losartan)
    +
    dipyridamole
    1 interaction

    Monitor/Modify Tx

    losartan + dipyridamole

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • doxapram
  • Arbli (losartan)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    losartan + doxapram

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • doxazosin
  • Arbli (losartan)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    losartan + doxazosin

    monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • doxepin
  • Arbli (losartan)
    +
    doxepin
    1 interaction

    Monitor/Modify Tx

    losartan + doxepin

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • dronabinol
  • Arbli (losartan)
    +
    dronabinol
    1 interaction

    Monitor/Modify Tx

    losartan + dronabinol

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • drospirenone (contraceptive)
  • Arbli (losartan)
    +
    drospirenone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    losartan + drospirenone (contraceptive)

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • drospirenone (hormone replacement)
  • Arbli (losartan)
    +
    drospirenone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    losartan + drospirenone (hormone replacement)

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • droxidopa
  • Arbli (losartan)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    losartan + droxidopa

    monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)

  • duloxetine
  • Arbli (losartan)
    +
    duloxetine
    1 interaction

    Monitor/Modify Tx

    losartan + duloxetine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • eletriptan
  • Arbli (losartan)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    losartan + eletriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • empagliflozin
  • Arbli (losartan)
    +
    empagliflozin
    1 interaction

    Monitor/Modify Tx

    losartan + empagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • entacapone
  • Arbli (losartan)
    +
    entacapone
    1 interaction

    Monitor/Modify Tx

    losartan + entacapone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • entrectinib
  • Arbli (losartan)
    +
    entrectinib
    1 interaction

    Monitor/Modify Tx

    losartan + entrectinib

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • ephedra
  • Arbli (losartan)
    +
    ephedra
    1 interaction

    Monitor/Modify Tx

    losartan + ephedra

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ephedrine injection
  • Arbli (losartan)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    losartan + ephedrine injection

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ephedrine oral
  • Arbli (losartan)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    losartan + ephedrine oral

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epinephrine
  • Arbli (losartan)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    losartan + epinephrine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epinephrine inhaled
  • Arbli (losartan)
    +
    epinephrine inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + epinephrine inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • eplerenone
  • Arbli (losartan)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    losartan + eplerenone

    monitor potassium, renal fxn: combo may incr. risk of hyperkalemia (additive effects)

  • epoetin alfa
  • Arbli (losartan)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    losartan + epoetin alfa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epoprostenol
  • Arbli (losartan)
    +
    epoprostenol
    1 interaction

    Monitor/Modify Tx

    losartan + epoprostenol

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • eptinezumab
  • Arbli (losartan)
    +
    eptinezumab
    1 interaction

    Monitor/Modify Tx

    losartan + eptinezumab

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • erenumab
  • Arbli (losartan)
    +
    erenumab
    1 interaction

    Monitor/Modify Tx

    losartan + erenumab

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ergotamine
  • Arbli (losartan)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    losartan + ergotamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ertugliflozin
  • Arbli (losartan)
    +
    ertugliflozin
    1 interaction

    Monitor/Modify Tx

    losartan + ertugliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • esketamine
  • Arbli (losartan)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    losartan + esketamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • estetrol (contraceptive)
  • Arbli (losartan)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    losartan + estetrol (contraceptive)

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • estradiol (contraceptive)
  • Arbli (losartan)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    losartan + estradiol (contraceptive)

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ethacrynic acid
  • Arbli (losartan)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    losartan + ethacrynic acid

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • ethanol (alcoholic beverage)
  • Arbli (losartan)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    losartan + ethanol (alcoholic beverage)

    monitor BP: combo may alter BP control, initially incr. risk of severe hypotension, followed by HTN (additive effects, antagonistic effects, acute alcohol intake may have biphasic effects on blood pressure; chronic alcohol use may further increase HTN risk)

  • ethanol injection
  • Arbli (losartan)
    +
    ethanol injection
    1 interaction

    Monitor/Modify Tx

    losartan + ethanol injection

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • ethinyl estradiol (contraceptive)
  • Arbli (losartan)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    losartan + ethinyl estradiol (contraceptive)

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • etodolac
  • Arbli (losartan)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    losartan + etodolac

    monitor BP, renal fxn, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of renal impairment, hyperkalemia (antagonistic effects; additive effects)

  • etrasimod
  • Arbli (losartan)
    +
    etrasimod
    1 interaction

    Monitor/Modify Tx

    losartan + etrasimod

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • etripamil nasal
  • Arbli (losartan)
    +
    etripamil nasal
    1 interaction

    Monitor/Modify Tx

    losartan + etripamil nasal

    monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)

  • fenfluramine
  • Arbli (losartan)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    losartan + fenfluramine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Arbli (losartan)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    losartan + fenoprofen

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • fentanyl
  • Arbli (losartan)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    losartan + fentanyl

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • ferumoxytol
  • Arbli (losartan)
    +
    ferumoxytol
    1 interaction

    Monitor/Modify Tx

    losartan + ferumoxytol

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • finerenone
  • Arbli (losartan)
    +
    finerenone
    1 interaction

    Monitor/Modify Tx

    losartan + finerenone

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • fingolimod
  • Arbli (losartan)
    +
    fingolimod
    1 interaction

    Monitor/Modify Tx

    losartan + fingolimod

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • flaxseed
  • Arbli (losartan)
    +
    flaxseed
    1 interaction

    Monitor/Modify Tx

    losartan + flaxseed

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • flibanserin
  • Arbli (losartan)
    +
    flibanserin
    1 interaction

    Monitor/Modify Tx

    losartan + flibanserin

    monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

  • flucytosine
  • Arbli (losartan)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    losartan + flucytosine

    monitor CBC, renal fxn, flucytosine levels: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • fludrocortisone
  • Arbli (losartan)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    losartan + fludrocortisone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fluphenazine
  • Arbli (losartan)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    losartan + fluphenazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • flurbiprofen
  • Arbli (losartan)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    losartan + flurbiprofen

    monitor BP, renal fxn, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of renal impairment, hyperkalemia (antagonistic effects; additive effects)

  • formoterol inhaled
  • Arbli (losartan)
    +
    formoterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + formoterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • foscarnet
  • Arbli (losartan)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    losartan + foscarnet

    monitor CBC, renal fxn: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • foslevodopa
  • Arbli (losartan)
    +
    foslevodopa
    1 interaction

    Monitor/Modify Tx

    losartan + foslevodopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fostamatinib
  • Arbli (losartan)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    losartan + fostamatinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fremanezumab
  • Arbli (losartan)
    +
    fremanezumab
    1 interaction

    Monitor/Modify Tx

    losartan + fremanezumab

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • frovatriptan
  • Arbli (losartan)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    losartan + frovatriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fruquintinib
  • Arbli (losartan)
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    losartan + fruquintinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • furosemide
  • Arbli (losartan)
    +
    furosemide
    1 interaction

    Monitor/Modify Tx

    losartan + furosemide

    monitor BP, renal fxn; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, renal impairment (additive effects)

  • galcanezumab
  • Arbli (losartan)
    +
    galcanezumab
    1 interaction

    Monitor/Modify Tx

    losartan + galcanezumab

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ganciclovir
  • Arbli (losartan)
    +
    ganciclovir
    1 interaction

    Monitor/Modify Tx

    losartan + ganciclovir

    monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • garlic
  • Arbli (losartan)
    +
    garlic
    1 interaction

    Monitor/Modify Tx

    losartan + garlic

    monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension (additive effects)

  • gentamicin
  • Arbli (losartan)
    +
    gentamicin
    1 interaction

    Monitor/Modify Tx

    losartan + gentamicin

    monitor gentamicin levels, renal fxn, ototoxicity: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • gilteritinib
  • Arbli (losartan)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    losartan + gilteritinib

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • glimepiride
  • Arbli (losartan)
    +
    glimepiride
    1 interaction

    Monitor/Modify Tx

    losartan + glimepiride

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • glipizide
  • Arbli (losartan)
    +
    glipizide
    1 interaction

    Monitor/Modify Tx

    losartan + glipizide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • glyburide
  • Arbli (losartan)
    +
    glyburide
    1 interaction

    Monitor/Modify Tx

    losartan + glyburide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • guanfacine
  • Arbli (losartan)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    losartan + guanfacine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • haloperidol
  • Arbli (losartan)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    losartan + haloperidol

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • heparin
  • Arbli (losartan)
    +
    heparin
    1 interaction

    Monitor/Modify Tx

    losartan + heparin

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • hoodia
  • Arbli (losartan)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    losartan + hoodia

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydralazine
  • Arbli (losartan)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    losartan + hydralazine

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • hydrochlorothiazide
  • Arbli (losartan)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    losartan + hydrochlorothiazide

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • hydrocodone
  • Arbli (losartan)
    +
    hydrocodone
    1 interaction

    Monitor/Modify Tx

    losartan + hydrocodone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • hydrocortisone
  • Arbli (losartan)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    losartan + hydrocortisone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydromorphone
  • Arbli (losartan)
    +
    hydromorphone
    1 interaction

    Monitor/Modify Tx

    losartan + hydromorphone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • hydroxocobalamin IV
  • Arbli (losartan)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    losartan + hydroxocobalamin IV

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ibrutinib
  • Arbli (losartan)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    losartan + ibrutinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ibuprofen
  • Arbli (losartan)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    losartan + ibuprofen

    monitor BP, renal fxn, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of renal impairment, hyperkalemia (antagonistic effects; additive effects)

  • ibuprofen lysine
  • Arbli (losartan)
    +
    ibuprofen lysine
    1 interaction

    Monitor/Modify Tx

    losartan + ibuprofen lysine

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • ifosfamide
  • Arbli (losartan)
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    losartan + ifosfamide

    monitor CBC, renal, cardiac fxn: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

  • iloperidone
  • Arbli (losartan)
    +
    iloperidone
    1 interaction

    Monitor/Modify Tx

    losartan + iloperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • iloprost
  • Arbli (losartan)
    +
    iloprost
    1 interaction

    Monitor/Modify Tx

    losartan + iloprost

    monitor BP; consider holding losartan during iloprost admin.: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

  • imipramine
  • Arbli (losartan)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    losartan + imipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • immune globulin
  • Arbli (losartan)
    +
    immune globulin
    1 interaction

    Monitor/Modify Tx

    losartan + immune globulin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • indapamide
  • Arbli (losartan)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    losartan + indapamide

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • indomethacin
  • Arbli (losartan)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    losartan + indomethacin

    monitor BP, renal fxn, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of renal impairment, hyperkalemia (additive effects; antagonistic effects)

  • insulin
  • Arbli (losartan)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    losartan + insulin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • iodixanol
  • Arbli (losartan)
    +
    iodixanol
    1 interaction

    Monitor/Modify Tx

    losartan + iodixanol

    monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)

  • iohexol
  • Arbli (losartan)
    +
    iohexol
    1 interaction

    Monitor/Modify Tx

    losartan + iohexol

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • iomeprol
  • Arbli (losartan)
    +
    iomeprol
    1 interaction

    Monitor/Modify Tx

    losartan + iomeprol

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • iopamidol
  • Arbli (losartan)
    +
    iopamidol
    1 interaction

    Monitor/Modify Tx

    losartan + iopamidol

    if IV iopamidol use, monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • iopromide
  • Arbli (losartan)
    +
    iopromide
    1 interaction

    Monitor/Modify Tx

    losartan + iopromide

    monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)

  • iothalamate meglumine
  • Arbli (losartan)
    +
    iothalamate meglumine
    1 interaction

    Monitor/Modify Tx

    losartan + iothalamate meglumine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ioversol
  • Arbli (losartan)
    +
    ioversol
    1 interaction

    Monitor/Modify Tx

    losartan + ioversol

    monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)

  • iron sucrose
  • Arbli (losartan)
    +
    iron sucrose
    1 interaction

    Monitor/Modify Tx

    losartan + iron sucrose

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • isoflurane
  • Arbli (losartan)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    losartan + isoflurane

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • isosorbide dinitrate
  • Arbli (losartan)
    +
    isosorbide dinitrate
    1 interaction

    Monitor/Modify Tx

    losartan + isosorbide dinitrate

    monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

  • isosorbide mononitrate
  • Arbli (losartan)
    +
    isosorbide mononitrate
    1 interaction

    Monitor/Modify Tx

    losartan + isosorbide mononitrate

    monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

  • ketamine
  • Arbli (losartan)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    losartan + ketamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ketoprofen
  • Arbli (losartan)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    losartan + ketoprofen

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • ketorolac
  • Arbli (losartan)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    losartan + ketorolac

    monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • landiolol
  • Arbli (losartan)
    +
    landiolol
    1 interaction

    Monitor/Modify Tx

    losartan + landiolol

    monitor BP, potassium, especially if renal impairment: combo may incr. risk of hypotension, hyperkalemia (additive effects)

  • lanreotide
  • Arbli (losartan)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    losartan + lanreotide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • leflunomide
  • Arbli (losartan)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    losartan + leflunomide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lenvatinib
  • Arbli (losartan)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    losartan + lenvatinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • levalbuterol inhaled
  • Arbli (losartan)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + levalbuterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • levobunolol ophthalmic
  • Arbli (losartan)
    +
    levobunolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + levobunolol ophthalmic

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • levodopa
  • Arbli (losartan)
    +
    levodopa
    1 interaction

    Monitor/Modify Tx

    losartan + levodopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • levomilnacipran
  • Arbli (losartan)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    losartan + levomilnacipran

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • levorphanol
  • Arbli (losartan)
    +
    levorphanol
    1 interaction

    Monitor/Modify Tx

    losartan + levorphanol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • levothyroxine
  • Arbli (losartan)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    losartan + levothyroxine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • licorice
  • Arbli (losartan)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    losartan + licorice

    monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lidocaine
  • Arbli (losartan)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    losartan + lidocaine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • liothyronine
  • Arbli (losartan)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    losartan + liothyronine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lisdexamfetamine
  • Arbli (losartan)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    losartan + lisdexamfetamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lithium
  • Arbli (losartan)
    +
    lithium
    1 interaction

    Monitor/Modify Tx

    losartan + lithium

    monitor lithium levels, renal fxn; consider decr. lithium start dose: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • lomustine
  • Arbli (losartan)
    +
    lomustine
    1 interaction

    Monitor/Modify Tx

    losartan + lomustine

    monitor CBC, renal fxn: combo may incr. lomustine levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • lorlatinib
  • Arbli (losartan)
    +
    lorlatinib
    1 interaction

    Monitor/Modify Tx

    losartan + lorlatinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • loxapine
  • Arbli (losartan)
    +
    loxapine
    1 interaction

    Monitor/Modify Tx

    losartan + loxapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lubiprostone
  • Arbli (losartan)
    +
    lubiprostone
    1 interaction

    Monitor/Modify Tx

    losartan + lubiprostone

    monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)

  • lumacaftor/ivacaftor
  • Arbli (losartan)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    losartan + lumacaftor/ ivacaftor

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lumateperone
  • Arbli (losartan)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    losartan + lumateperone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lurasidone
  • Arbli (losartan)
    +
    lurasidone
    1 interaction

    Monitor/Modify Tx

    losartan + lurasidone

    monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • luspatercept
  • Arbli (losartan)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    losartan + luspatercept

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lutetium Lu 177 vipivotide tetraxetan
  • Arbli (losartan)
    +
    lutetium Lu 177 vipivotide tetraxetan
    1 interaction

    Monitor/Modify Tx

    losartan + lutetium Lu 177 vipivotide tetraxetan

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium citrate
  • Arbli (losartan)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    losartan + magnesium citrate

    monitor renal fxn, especially if magnesium citrate bowel prep use: combo may incr. risk of renal impairment (additive effects)

  • magnesium salicylate
  • Arbli (losartan)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    losartan + magnesium salicylate

    monitor renal fxn, BP w/ high-dose magnesium salicylate: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • magnesium sulfate
  • Arbli (losartan)
    +
    magnesium sulfate
    1 interaction

    Monitor/Modify Tx

    losartan + magnesium sulfate

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • maraviroc
  • Arbli (losartan)
    +
    maraviroc
    1 interaction

    Monitor/Modify Tx

    losartan + maraviroc

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • meclofenamate
  • Arbli (losartan)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    losartan + meclofenamate

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • mefenamic acid
  • Arbli (losartan)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    losartan + mefenamic acid

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • meloxicam
  • Arbli (losartan)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    losartan + meloxicam

    monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • meperidine
  • Arbli (losartan)
    +
    meperidine
    1 interaction

    Monitor/Modify Tx

    losartan + meperidine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • mepivacaine
  • Arbli (losartan)
    +
    mepivacaine
    1 interaction

    Monitor/Modify Tx

    losartan + mepivacaine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • mesalamine
  • Arbli (losartan)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    losartan + mesalamine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • mesalamine rectal
  • Arbli (losartan)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    losartan + mesalamine rectal

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • methadone
  • Arbli (losartan)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    losartan + methadone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • methamphetamine
  • Arbli (losartan)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    losartan + methamphetamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methohexital
  • Arbli (losartan)
    +
    methohexital
    1 interaction

    Monitor/Modify Tx

    losartan + methohexital

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • methotrexate
  • Arbli (losartan)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    losartan + methotrexate

    monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Arbli (losartan)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    losartan + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylene blue injection
  • Arbli (losartan)
    +
    methylene blue injection
    1 interaction

    Monitor/Modify Tx

    losartan + methylene blue injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • methylergonovine
  • Arbli (losartan)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    losartan + methylergonovine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylphenidate
  • Arbli (losartan)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    losartan + methylphenidate

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylprednisolone
  • Arbli (losartan)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    losartan + methylprednisolone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methyltestosterone
  • Arbli (losartan)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    losartan + methyltestosterone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • metoclopramide
  • Arbli (losartan)
    +
    metoclopramide
    1 interaction

    Monitor/Modify Tx

    losartan + metoclopramide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • metolazone
  • Arbli (losartan)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    losartan + metolazone

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • midazolam
  • Arbli (losartan)
    +
    midazolam
    1 interaction

    Monitor/Modify Tx

    losartan + midazolam

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • midodrine
  • Arbli (losartan)
    +
    midodrine
    1 interaction

    Monitor/Modify Tx

    losartan + midodrine

    monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)

  • milnacipran
  • Arbli (losartan)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    losartan + milnacipran

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • milrinone
  • Arbli (losartan)
    +
    milrinone
    1 interaction

    Monitor/Modify Tx

    losartan + milrinone

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • milsaperidone
  • Arbli (losartan)
    +
    milsaperidone
    1 interaction

    Monitor/Modify Tx

    losartan + milsaperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mirabegron
  • Arbli (losartan)
    +
    mirabegron
    1 interaction

    Monitor/Modify Tx

    losartan + mirabegron

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirtazapine
  • Arbli (losartan)
    +
    mirtazapine
    1 interaction

    Monitor/Modify Tx

    losartan + mirtazapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • mitomycin
  • Arbli (losartan)
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    losartan + mitomycin

    monitor renal fxn; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of nephrotoxicity (additive effects)

  • modafinil
  • Arbli (losartan)
    +
    modafinil
    1 interaction

    Monitor/Modify Tx

    losartan + modafinil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • molindone
  • Arbli (losartan)
    +
    molindone
    1 interaction

    Monitor/Modify Tx

    losartan + molindone

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • morphine
  • Arbli (losartan)
    +
    morphine
    1 interaction

    Monitor/Modify Tx

    losartan + morphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • nabumetone
  • Arbli (losartan)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    losartan + nabumetone

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • nalbuphine
  • Arbli (losartan)
    +
    nalbuphine
    1 interaction

    Monitor/Modify Tx

    losartan + nalbuphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • naphazoline ophthalmic
  • Arbli (losartan)
    +
    naphazoline ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + naphazoline ophthalmic

    consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • naproxen
  • Arbli (losartan)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    losartan + naproxen

    monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • naratriptan
  • Arbli (losartan)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    losartan + naratriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nateglinide
  • Arbli (losartan)
    +
    nateglinide
    1 interaction

    Monitor/Modify Tx

    losartan + nateglinide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • nattokinase
  • Arbli (losartan)
    +
    nattokinase
    1 interaction

    Monitor/Modify Tx

    losartan + nattokinase

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • naxitamab
  • Arbli (losartan)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    losartan + naxitamab

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • neomycin
  • Arbli (losartan)
    +
    neomycin
    1 interaction

    Monitor/Modify Tx

    losartan + neomycin

    if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • niacin (vitamin B3)
  • Arbli (losartan)
    +
    niacin (vitamin B3)
    1 interaction

    Monitor/Modify Tx

    losartan + niacin (vitamin B3)

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • nilotinib
  • Arbli (losartan)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    losartan + nilotinib

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • niraparib
  • Arbli (losartan)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    losartan + niraparib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nitric oxide
  • Arbli (losartan)
    +
    nitric oxide
    1 interaction

    Monitor/Modify Tx

    losartan + nitric oxide

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • nitrite
  • Arbli (losartan)
    +
    nitrite
    1 interaction

    Monitor/Modify Tx

    losartan + nitrite

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including syncope (additive effects)

  • nitroglycerin
  • Arbli (losartan)
    +
    nitroglycerin
    1 interaction

    Monitor/Modify Tx

    losartan + nitroglycerin

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • nitroprusside
  • Arbli (losartan)
    +
    nitroprusside
    1 interaction

    Monitor/Modify Tx

    losartan + nitroprusside

    monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)

  • nortriptyline
  • Arbli (losartan)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    losartan + nortriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • nusinersen
  • Arbli (losartan)
    +
    nusinersen
    1 interaction

    Monitor/Modify Tx

    losartan + nusinersen

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • obinutuzumab
  • Arbli (losartan)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    losartan + obinutuzumab

    monitor BP: combo may incr. risk of hypotension; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • olanzapine
  • Arbli (losartan)
    +
    olanzapine
    1 interaction

    Monitor/Modify Tx

    losartan + olanzapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • oliceridine
  • Arbli (losartan)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    losartan + oliceridine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • olodaterol inhaled
  • Arbli (losartan)
    +
    olodaterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + olodaterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • olsalazine
  • Arbli (losartan)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    losartan + olsalazine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • opicapone
  • Arbli (losartan)
    +
    opicapone
    1 interaction

    Monitor/Modify Tx

    losartan + opicapone

    monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • opium
  • Arbli (losartan)
    +
    opium
    1 interaction

    Monitor/Modify Tx

    losartan + opium

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • osilodrostat
  • Arbli (losartan)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    losartan + osilodrostat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • oxaliplatin
  • Arbli (losartan)
    +
    oxaliplatin
    1 interaction

    Monitor/Modify Tx

    losartan + oxaliplatin

    monitor ECG, CBC, renal fxn, ototoxicity: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • oxaprozin
  • Arbli (losartan)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    losartan + oxaprozin

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • oxazepam
  • Arbli (losartan)
    +
    oxazepam
    1 interaction

    Monitor/Modify Tx

    losartan + oxazepam

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • oxycodone
  • Arbli (losartan)
    +
    oxycodone
    1 interaction

    Monitor/Modify Tx

    losartan + oxycodone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • oxymetazoline nasal
  • Arbli (losartan)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    losartan + oxymetazoline nasal

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • oxymetazoline ophthalmic
  • Arbli (losartan)
    +
    oxymetazoline ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + oxymetazoline ophthalmic

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • oxymetazoline topical
  • Arbli (losartan)
    +
    oxymetazoline topical
    1 interaction

    Monitor/Modify Tx

    losartan + oxymetazoline topical

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • oxymorphone
  • Arbli (losartan)
    +
    oxymorphone
    1 interaction

    Monitor/Modify Tx

    losartan + oxymorphone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • oxytocin
  • Arbli (losartan)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    losartan + oxytocin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ozanimod
  • Arbli (losartan)
    +
    ozanimod
    1 interaction

    Monitor/Modify Tx

    losartan + ozanimod

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • paliperidone
  • Arbli (losartan)
    +
    paliperidone
    1 interaction

    Monitor/Modify Tx

    losartan + paliperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • palopegteriparatide
  • Arbli (losartan)
    +
    palopegteriparatide
    1 interaction

    Monitor/Modify Tx

    losartan + palopegteriparatide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • pamidronate
  • Arbli (losartan)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    losartan + pamidronate

    monitor renal fxn: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • paromomycin
  • Arbli (losartan)
    +
    paromomycin
    1 interaction

    Monitor/Modify Tx

    losartan + paromomycin

    if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pazopanib
  • Arbli (losartan)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    losartan + pazopanib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pemetrexed
  • Arbli (losartan)
    +
    pemetrexed
    1 interaction

    Monitor/Modify Tx

    losartan + pemetrexed

    monitor CBC, renal fxn: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • penicillamine
  • Arbli (losartan)
    +
    penicillamine
    1 interaction

    Monitor/Modify Tx

    losartan + penicillamine

    monitor CBC, renal fxn: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • pentamidine
  • Arbli (losartan)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    losartan + pentamidine

    monitor renal fxn, BP: combo may incr. risk of nephrotoxicity, severe or life-threatening hypotension (additive effects)

  • pentazocine
  • Arbli (losartan)
    +
    pentazocine
    1 interaction

    Monitor/Modify Tx

    losartan + pentazocine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • pentobarbital
  • Arbli (losartan)
    +
    pentobarbital
    1 interaction

    Monitor/Modify Tx

    losartan + pentobarbital

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • pentostatin
  • Arbli (losartan)
    +
    pentostatin
    1 interaction

    Monitor/Modify Tx

    losartan + pentostatin

    monitor CBC, renal fxn: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • pentoxifylline
  • Arbli (losartan)
    +
    pentoxifylline
    1 interaction

    Monitor/Modify Tx

    losartan + pentoxifylline

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • perphenazine
  • Arbli (losartan)
    +
    perphenazine
    1 interaction

    Monitor/Modify Tx

    losartan + perphenazine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • pexidartinib
  • Arbli (losartan)
    +
    pexidartinib
    1 interaction

    Monitor/Modify Tx

    losartan + pexidartinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phendimetrazine
  • Arbli (losartan)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    losartan + phendimetrazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenelzine
  • Arbli (losartan)
    +
    phenelzine
    1 interaction

    Monitor/Modify Tx

    losartan + phenelzine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • phenobarbital
  • Arbli (losartan)
    +
    phenobarbital
    1 interaction

    Monitor/Modify Tx

    losartan + phenobarbital

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • phentermine
  • Arbli (losartan)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    losartan + phentermine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Arbli (losartan)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    losartan + phenylephrine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine injection
  • Arbli (losartan)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    losartan + phenylephrine injection

    monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)

  • phenylephrine nasal
  • Arbli (losartan)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    losartan + phenylephrine nasal

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine ophthalmic
  • Arbli (losartan)
    +
    phenylephrine ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + phenylephrine ophthalmic

    monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine rectal
  • Arbli (losartan)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    losartan + phenylephrine rectal

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • piroxicam
  • Arbli (losartan)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    losartan + piroxicam

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • plazomicin
  • Arbli (losartan)
    +
    plazomicin
    1 interaction

    Monitor/Modify Tx

    losartan + plazomicin

    monitor plazomicin levels, renal fxn, ototoxicity: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • polyethylene glycol
  • Arbli (losartan)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    losartan + polyethylene glycol

    monitor renal fxn, especially if polyethylene glycol bowel prep use: combo may incr. risk of renal impairment (additive effects)

  • polyethylene glycol/electrolytes
  • Arbli (losartan)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    losartan + polyethylene glycol/ electrolytes

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • polymyxin B
  • Arbli (losartan)
    +
    polymyxin B
    1 interaction

    Monitor/Modify Tx

    losartan + polymyxin B

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ponatinib
  • Arbli (losartan)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    losartan + ponatinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ponesimod
  • Arbli (losartan)
    +
    ponesimod
    1 interaction

    Monitor/Modify Tx

    losartan + ponesimod

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • potassium acid phosphate
  • Arbli (losartan)
    +
    potassium acid phosphate
    1 interaction

    Monitor/Modify Tx

    losartan + potassium acid phosphate

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • potassium bicarbonate
  • Arbli (losartan)
    +
    potassium bicarbonate
    1 interaction

    Monitor/Modify Tx

    losartan + potassium bicarbonate

    monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • potassium citrate
  • Arbli (losartan)
    +
    potassium citrate
    1 interaction

    Monitor/Modify Tx

    losartan + potassium citrate

    monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • potassium iodide
  • Arbli (losartan)
    +
    potassium iodide
    1 interaction

    Monitor/Modify Tx

    losartan + potassium iodide

    monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • pralsetinib
  • Arbli (losartan)
    +
    pralsetinib
    1 interaction

    Monitor/Modify Tx

    losartan + pralsetinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pramipexole
  • Arbli (losartan)
    +
    pramipexole
    1 interaction

    Monitor/Modify Tx

    losartan + pramipexole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • prazosin
  • Arbli (losartan)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    losartan + prazosin

    monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • prednisolone
  • Arbli (losartan)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    losartan + prednisolone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisone
  • Arbli (losartan)
    +
    prednisone
    1 interaction

    Monitor/Modify Tx

    losartan + prednisone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • procarbazine
  • Arbli (losartan)
    +
    procarbazine
    1 interaction

    Monitor/Modify Tx

    losartan + procarbazine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • prochlorperazine
  • Arbli (losartan)
    +
    prochlorperazine
    1 interaction

    Monitor/Modify Tx

    losartan + prochlorperazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • promethazine
  • Arbli (losartan)
    +
    promethazine
    1 interaction

    Monitor/Modify Tx

    losartan + promethazine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • propafenone
  • Arbli (losartan)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    losartan + propafenone

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • propofol
  • Arbli (losartan)
    +
    propofol
    1 interaction

    Monitor/Modify Tx

    losartan + propofol

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • protriptyline
  • Arbli (losartan)
    +
    protriptyline
    1 interaction

    Monitor/Modify Tx

    losartan + protriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • pseudoephedrine
  • Arbli (losartan)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    losartan + pseudoephedrine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • quetiapine
  • Arbli (losartan)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    losartan + quetiapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antihypertensive agent efficacy (peds patients) (additive effects, antagonistic effects)

  • ramucirumab
  • Arbli (losartan)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    losartan + ramucirumab

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • rasagiline
  • Arbli (losartan)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    losartan + rasagiline

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • regorafenib
  • Arbli (losartan)
    +
    regorafenib
    1 interaction

    Monitor/Modify Tx

    losartan + regorafenib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • remifentanil
  • Arbli (losartan)
    +
    remifentanil
    1 interaction

    Monitor/Modify Tx

    losartan + remifentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • remimazolam
  • Arbli (losartan)
    +
    remimazolam
    1 interaction

    Monitor/Modify Tx

    losartan + remimazolam

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • repaglinide
  • Arbli (losartan)
    +
    repaglinide
    1 interaction

    Monitor/Modify Tx

    losartan + repaglinide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • Rho(D) immune globulin
  • Arbli (losartan)
    +
    Rho(D) immune globulin
    1 interaction

    Monitor/Modify Tx

    losartan + Rho(D) immune globulin

    monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • rimegepant
  • Arbli (losartan)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    losartan + rimegepant

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • riociguat
  • Arbli (losartan)
    +
    riociguat
    1 interaction

    Monitor/Modify Tx

    losartan + riociguat

    monitor BP: combo may incr. risk of severe hypotension (additive effects)

  • ripretinib
  • Arbli (losartan)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    losartan + ripretinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • risperidone
  • Arbli (losartan)
    +
    risperidone
    1 interaction

    Monitor/Modify Tx

    losartan + risperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • rituximab
  • Arbli (losartan)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    losartan + rituximab

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • rizatriptan
  • Arbli (losartan)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    losartan + rizatriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ropeginterferon alfa-2b
  • Arbli (losartan)
    +
    ropeginterferon alfa-2b
    1 interaction

    Monitor/Modify Tx

    losartan + ropeginterferon alfa-2b

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ropinirole
  • Arbli (losartan)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    losartan + ropinirole

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • ropivacaine
  • Arbli (losartan)
    +
    ropivacaine
    1 interaction

    Monitor/Modify Tx

    losartan + ropivacaine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • rotigotine transdermal
  • Arbli (losartan)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    losartan + rotigotine transdermal

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • sacubitril
  • Arbli (losartan)
    +
    sacubitril
    1 interaction

    Monitor/Modify Tx

    losartan + sacubitril

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • safinamide
  • Arbli (losartan)
    +
    safinamide
    1 interaction

    Monitor/Modify Tx

    losartan + safinamide

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • salmeterol inhaled
  • Arbli (losartan)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + salmeterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • salsalate
  • Arbli (losartan)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    losartan + salsalate

    monitor renal fxn, BP w/ high-dose salsalate: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • selegiline
  • Arbli (losartan)
    +
    selegiline
    1 interaction

    Monitor/Modify Tx

    losartan + selegiline

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • selegiline transdermal
  • Arbli (losartan)
    +
    selegiline transdermal
    1 interaction

    Monitor/Modify Tx

    losartan + selegiline transdermal

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • selpercatinib
  • Arbli (losartan)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    losartan + selpercatinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sevoflurane
  • Arbli (losartan)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    losartan + sevoflurane

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • sildenafil
  • Arbli (losartan)
    +
    sildenafil
    1 interaction

    Monitor/Modify Tx

    losartan + sildenafil

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • silodosin
  • Arbli (losartan)
    +
    silodosin
    1 interaction

    Monitor/Modify Tx

    losartan + silodosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • siponimod
  • Arbli (losartan)
    +
    siponimod
    1 interaction

    Monitor/Modify Tx

    losartan + siponimod

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sirolimus
  • Arbli (losartan)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    losartan + sirolimus

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • sitagliptin
  • Arbli (losartan)
    +
    sitagliptin
    1 interaction

    Monitor/Modify Tx

    losartan + sitagliptin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • sodium ferric gluconate complex
  • Arbli (losartan)
    +
    sodium ferric gluconate complex
    1 interaction

    Monitor/Modify Tx

    losartan + sodium ferric gluconate complex

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • sorafenib
  • Arbli (losartan)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    losartan + sorafenib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sotagliflozin
  • Arbli (losartan)
    +
    sotagliflozin
    1 interaction

    Monitor/Modify Tx

    losartan + sotagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • sotalol
  • Arbli (losartan)
    +
    sotalol
    1 interaction

    Monitor/Modify Tx

    losartan + sotalol

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • spironolactone
  • Arbli (losartan)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    losartan + spironolactone

    monitor renal fxn, potassium: combo may incr. risk of renal impairment, severe hyperkalemia (additive effects)

  • streptomycin
  • Arbli (losartan)
    +
    streptomycin
    1 interaction

    Monitor/Modify Tx

    losartan + streptomycin

    monitor renal fxn, ototoxicity: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • streptozocin
  • Arbli (losartan)
    +
    streptozocin
    1 interaction

    Monitor/Modify Tx

    losartan + streptozocin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • succinylcholine
  • Arbli (losartan)
    +
    succinylcholine
    1 interaction

    Monitor/Modify Tx

    losartan + succinylcholine

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • sufentanil
  • Arbli (losartan)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    losartan + sufentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • sulfate bowel prep
  • Arbli (losartan)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    losartan + sulfate bowel prep

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • sulindac
  • Arbli (losartan)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    losartan + sulindac

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • sumatriptan
  • Arbli (losartan)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    losartan + sumatriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sunitinib
  • Arbli (losartan)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    losartan + sunitinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tadalafil
  • Arbli (losartan)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    losartan + tadalafil

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • tagraxofusp
  • Arbli (losartan)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    losartan + tagraxofusp

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • tamsulosin
  • Arbli (losartan)
    +
    tamsulosin
    1 interaction

    Monitor/Modify Tx

    losartan + tamsulosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tapentadol
  • Arbli (losartan)
    +
    tapentadol
    1 interaction

    Monitor/Modify Tx

    losartan + tapentadol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • taurine
  • Arbli (losartan)
    +
    taurine
    1 interaction

    Monitor/Modify Tx

    losartan + taurine

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • telavancin
  • Arbli (losartan)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    losartan + telavancin

    monitor ECG, renal fxn: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)

  • temsirolimus
  • Arbli (losartan)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    losartan + temsirolimus

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tenofovir alafenamide
  • Arbli (losartan)
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    losartan + tenofovir alafenamide

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • tenofovir disoproxil
  • Arbli (losartan)
    +
    tenofovir disoproxil
    1 interaction

    Monitor/Modify Tx

    losartan + tenofovir disoproxil

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • terazosin
  • Arbli (losartan)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    losartan + terazosin

    monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • terbutaline
  • Arbli (losartan)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    losartan + terbutaline

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • teriflunomide
  • Arbli (losartan)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    losartan + teriflunomide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • testosterone
  • Arbli (losartan)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    losartan + testosterone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tetrahydrozoline ophthalmic
  • Arbli (losartan)
    +
    tetrahydrozoline ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + tetrahydrozoline ophthalmic

    consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • thalidomide
  • Arbli (losartan)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    losartan + thalidomide

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • thioridazine
  • Arbli (losartan)
    +
    thioridazine
    1 interaction

    Monitor/Modify Tx

    losartan + thioridazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • thiothixene
  • Arbli (losartan)
    +
    thiothixene
    1 interaction

    Monitor/Modify Tx

    losartan + thiothixene

    monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)

  • thyroid
  • Arbli (losartan)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    losartan + thyroid

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • timolol ophthalmic
  • Arbli (losartan)
    +
    timolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    losartan + timolol ophthalmic

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • tiopronin
  • Arbli (losartan)
    +
    tiopronin
    1 interaction

    Monitor/Modify Tx

    losartan + tiopronin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tivozanib
  • Arbli (losartan)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    losartan + tivozanib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tizanidine
  • Arbli (losartan)
    +
    tizanidine
    1 interaction

    Monitor/Modify Tx

    losartan + tizanidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tobramycin
  • Arbli (losartan)
    +
    tobramycin
    1 interaction

    Monitor/Modify Tx

    losartan + tobramycin

    monitor tobramycin levels, renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • tobramycin inhaled
  • Arbli (losartan)
    +
    tobramycin inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + tobramycin inhaled

    monitor renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • tolcapone
  • Arbli (losartan)
    +
    tolcapone
    1 interaction

    Monitor/Modify Tx

    losartan + tolcapone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tolmetin
  • Arbli (losartan)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    losartan + tolmetin

    monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • tolvaptan
  • Arbli (losartan)
    +
    tolvaptan
    1 interaction

    Monitor/Modify Tx

    losartan + tolvaptan

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • torsemide
  • Arbli (losartan)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    losartan + torsemide

    monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

  • tramadol
  • Arbli (losartan)
    +
    tramadol
    1 interaction

    Monitor/Modify Tx

    losartan + tramadol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • trametinib
  • Arbli (losartan)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    losartan + trametinib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tranylcypromine
  • Arbli (losartan)
    +
    tranylcypromine
    1 interaction

    Monitor/Modify Tx

    losartan + tranylcypromine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • trazodone
  • Arbli (losartan)
    +
    trazodone
    1 interaction

    Monitor/Modify Tx

    losartan + trazodone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • treprostinil
  • Arbli (losartan)
    +
    treprostinil
    1 interaction

    Monitor/Modify Tx

    losartan + treprostinil

    monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

  • triamcinolone
  • Arbli (losartan)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    losartan + triamcinolone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triamterene
  • Arbli (losartan)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    losartan + triamterene

    monitor potassium: combo may incr. risk of severe hyperkalemia (additive effects)

  • trifluoperazine
  • Arbli (losartan)
    +
    trifluoperazine
    1 interaction

    Monitor/Modify Tx

    losartan + trifluoperazine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

  • trimipramine
  • Arbli (losartan)
    +
    trimipramine
    1 interaction

    Monitor/Modify Tx

    losartan + trimipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

  • ubrogepant
  • Arbli (losartan)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    losartan + ubrogepant

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vaccinia immune globulin
  • Arbli (losartan)
    +
    vaccinia immune globulin
    1 interaction

    Monitor/Modify Tx

    losartan + vaccinia immune globulin

    monitor renal fxn; use lowest vaccinia immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • vadadustat
  • Arbli (losartan)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    losartan + vadadustat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • valacyclovir
  • Arbli (losartan)
    +
    valacyclovir
    1 interaction

    Monitor/Modify Tx

    losartan + valacyclovir

    monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • valganciclovir
  • Arbli (losartan)
    +
    valganciclovir
    1 interaction

    Monitor/Modify Tx

    losartan + valganciclovir

    monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • vamorolone
  • Arbli (losartan)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    losartan + vamorolone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vancomycin
  • Arbli (losartan)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    losartan + vancomycin

    VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)

  • vandetanib
  • Arbli (losartan)
    +
    vandetanib
    1 interaction

    Monitor/Modify Tx

    losartan + vandetanib

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vardenafil
  • Arbli (losartan)
    +
    vardenafil
    1 interaction

    Monitor/Modify Tx

    losartan + vardenafil

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • vasopressin
  • Arbli (losartan)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    losartan + vasopressin

    monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)

  • venlafaxine
  • Arbli (losartan)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    losartan + venlafaxine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vilanterol inhaled
  • Arbli (losartan)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    losartan + vilanterol inhaled

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • viloxazine
  • Arbli (losartan)
    +
    viloxazine
    1 interaction

    Monitor/Modify Tx

    losartan + viloxazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • voclosporin
  • Arbli (losartan)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    losartan + voclosporin

    monitor potassium, renal fxn, BP: combo may incr. risk of severe hyperkalemia, nephrotoxicity; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • vosoritide
  • Arbli (losartan)
    +
    vosoritide
    1 interaction

    Monitor/Modify Tx

    losartan + vosoritide

    monitor BP: combo may incr. risk of hypotension (additive effects)

  • willow bark
  • Arbli (losartan)
    +
    willow bark
    1 interaction

    Monitor/Modify Tx

    losartan + willow bark

    monitor renal fxn, especially w/ high-dose willow bark: combo may incr. risk of renal impairment (additive effects, willow bark may contain salicylates)

  • yohimbe
  • Arbli (losartan)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    losartan + yohimbe

    monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)

  • zavegepant
  • Arbli (losartan)
    +
    zavegepant
    1 interaction

    Monitor/Modify Tx

    losartan + zavegepant

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ziprasidone
  • Arbli (losartan)
    +
    ziprasidone
    1 interaction

    Monitor/Modify Tx

    losartan + ziprasidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ziv-aflibercept
  • Arbli (losartan)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    losartan + ziv-aflibercept

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • zoledronic acid
  • Arbli (losartan)
    +
    zoledronic acid
    1 interaction

    Monitor/Modify Tx

    losartan + zoledronic acid

    monitor renal fxn: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • zolmitriptan
  • Arbli (losartan)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    losartan + zolmitriptan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

Caution Advised

  • rifampin
  • Arbli (losartan)
    +
    rifampin
    1 interaction

    Caution Advised

    losartan + rifampin

    caution advised: combo may decr. losartan levels, efficacy (hepatic metabolism possibly induced)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@1c78fc04
  • angioedema
  • anaphylaxis
  • hypotension, severe
  • hyperkalemia
  • renal failure
  • renal impairment
  • rhabdomyolysis
  • hepatitis
  • thrombocytopenia

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@10024109
  • URI
  • diarrhea
  • fatigue
  • asthenia
  • musculoskeletal pain
  • chest pain
  • cough
  • hypotension
  • hyperkalemia
  • dyspepsia
  • dizziness

Safety/Monitoring .

Monitoring Parameters
BUN/Cr at baseline, then periodically; electrolytes; BP

Look/Sound-Alike Drug Names
losartan confused with: lisinopril; loratadine; lovastatin; valsartan

Pregnancy/Lactation .

Pregnancy

Clinical Summary

avoid use during pregnancy; if must use, monitor amniotic fluid and fetus closely; risk of fetal and neonatal harm, including intrauterine growth restriction, oligohydramnios, renal failure, and death, in 2nd and 3rd trimesters based on human data and drug's mechanism of action

Lactation

Clinical Summary

weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@763a455c

Metabolism: for losartan: liver; CYP450: 2C9 (primary), 3A4 substrate; Info: active metabolite

Excretion: for losartan: feces 60%, urine 35% (4% unchanged); Half-life: 2h (parent drug), 6-9h (active metabolite)

Subclass: Angiotensin Receptor Blockers (ARBs)

Mechanism of Action
for losartan: selectively antagonizes angiotensin II AT1 receptors

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Scienture LLC

com.epocrates.rxweb.beans.DrugOtherInfoBean@1e43c9d

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information